NASDAQ · HOWL
Healthcare · Biotechnology
$1.05
Up+$0.01 (+0.96%)
Updated Oct 21, 2026, 11:33 AM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · HOWL
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 20, 2026
HOWL closed at $1.05 after 21 trading sessions, up 6.92% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 20, 2026 | $1.03 | $1.09 | $1.03 | $1.05 | 485.74K |
| Oct 19, 2026 | $0.9792 | $1.055 | $0.9792 | $1.04 | 378.85K |
| Oct 16, 2026 | $1.01 | $1.01 | $0.9703 | $0.98 | 309.25K |
| Oct 15, 2026 | $0.9615 | $1.0176 | $0.9615 | $0.997 | 426.22K |
| Oct 14, 2026 | $0.99 | $1.025 | $0.9657 | $0.98 | 664.07K |
| Oct 13, 2026 | $1.00 | $1.0101 | $0.97 | $0.9911 | 355.21K |
| Oct 12, 2026 | $0.98 | $1.02 | $0.9601 | $0.9818 | 811.41K |
| Oct 9, 2026 | $0.93 | $0.99 | $0.9201 | $0.9796 | 704.63K |
| Oct 8, 2026 | $0.92 | $0.9281 | $0.907 | $0.91 | 631.37K |
| Oct 7, 2026 | $0.916 | $0.9246 | $0.9077 | $0.9201 | 381.62K |
| Oct 6, 2026 | $0.94 | $0.94 | $0.9101 | $0.9202 | 279.15K |
| Oct 5, 2026 | $0.93 | $0.9499 | $0.91 | $0.93 | 239.08K |
| Oct 2, 2026 | $0.89 | $0.9397 | $0.89 | $0.9281 | 471.3K |
| Oct 1, 2026 | $0.92 | $0.925 | $0.8812 | $0.8815 | 299.33K |
| Sep 30, 2026 | $0.91 | $0.9397 | $0.8901 | $0.9223 | 829.17K |
| Sep 29, 2026 | $0.94 | $0.9504 | $0.88 | $0.91 | 974.19K |
| Sep 28, 2026 | $0.97 | $0.97 | $0.925 | $0.93 | 701.24K |
| Sep 25, 2026 | $0.975 | $0.9826 | $0.9599 | $0.9599 | 454.93K |
| Sep 24, 2026 | $0.9852 | $0.9899 | $0.967 | $0.981 | 228.27K |
| Sep 23, 2026 | $0.9739 | $0.9898 | $0.9699 | $0.9894 | 316.71K |
| Sep 22, 2026 | $0.99 | $0.995 | $0.9706 | $0.982 | 375.93K |
The latest Smart Investors Daily articles mentioning HOWL.
Company
Market Activity
Research & News
HOWL research
Company profile and research snapshot.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 19, 2025 | HC Wainwright & Co. | Buy | — |
| Nov 18, 2025 | B of A Securities | Buy | — |
| Aug 25, 2025 | B of A Securities | Buy | — |
| Aug 21, 2025 | JMP Securities | Market Outperform | — |
| May 9, 2025 | Wedbush | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 13, 2026
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Yahoo · Oct 9, 2026
LITE, HOWL, PERI, GSBD and GFF have been added to the Zacks Rank #1 (Strong Buy) List on October 9th, 2026.
Yahoo · Oct 7, 2026
Halozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.
Benzinga · Aug 21, 2026
Dow gains 400 points, Materials sector up 2.3%, Werewolf Therapeutics up 113%, S&P PMI rises to strongest level since April 2022.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HOWL.
